An interventional study of glucose and insulin infusions in Hyperglycemia and Diabetes, sponsored by Admetsys Corporation. Active, not recruiting at 1 site in United States. Open to participants aged 21 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Admetsys Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 316 studies in Hyperglycemia with a site in United States — 29 open to participants now, 38 under way, 1 of them phase 3. Hyperglycemia · United States.
Among the 316 studies in Hyperglycemia with a site in United States, this one is the 141st largest by planned enrollment of the 265 interventional ones that give a count, is one of 25 that started in 2008, is one of 143 with no phase, reaches primary completion later than 34 of the 37 other live ones, and was the 122nd registered.
802 studies on the registry are indexed under Hyperglycemia; 115 are open to participants now.
Browse Hyperglycemia studies →29 of the 316 studies in Hyperglycemia with a site in United States are open now. Recruiting first, the newest first:
University of Pittsburgh · Sites in United States
Ages 14–26
Indiana University · Sites in United States
Ages 7–25
University of Pittsburgh · Sites in United States
Ages 16–24
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Men only
David K Carroll · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 71 Hyperglycemia studies recruiting now, 42 (59%) set no upper age limit and 23 (32%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 21 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
316 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 30 · Phase 3 27 · Phase 4 43
First in 1998; this study’s year is marked. 25 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 50 across 622 interventional studies indexed under Hyperglycemia.
Median enrollment 48 across the 265 interventional studies, 84 across the 50 observational. Of the 258 that completed or were terminated, 111 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 316 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Admetsys Corporation as lead sponsor.
Admetsys Corporation has 1 study filed under Hyperglycemia — fewer than ten, so there is no comparison to draw.
20 of the studies in Hyperglycemia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07215312Eli Lilly and CompanyA Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin | 2026-11 |
| NCT07216508Icahn School of Medicine at Mount SinaiLiver Transplant CGM | 2026-11-30 |
| NCT05455619SynDevRx, Inc.Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer | 2026-12 |
| NCT07270016University of PittsburghPilot-Testing Real-Time Engagement for Learning to Effectively Control Type 2 Diabetes | 2026-12 |
| NCT06893341Indiana UniversityMonitoring Exhaled Breath to Noninvasively Detect Glycemic Events | 2026-12-01 |
Add all 20 to your calendar (.ics) → With an account.
Among the 316 studies in Hyperglycemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to study the use of a counterbalancing system of glucose and insulin infusion with frequent blood glucose monitoring and combined adaptive algorithm can produce tight glycemic control without hypoglycemia; study to develop a closed loop for use in intensive care units and surgery
The study is using an experimental design outpatient with individuals having treatment using an automated closed loop glucose control unit; glucoses are measured every 5 minutes using a intravenous glucose sensor and infusion of glucose and insulin are altered without manual intervention as directed by algorithm
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
trial of experimental technique in outpatient setting; the group under study will be comprised of type 1 and type 2 diabetic individuals ; they will have automated treatment using algorithm which regulates balancing infusions of glucose and/or insulin intravenously without manual intervention; blood glucose target of 80-180 mg/dl will be guide for the automated system
Device: glucose and insulin infusions
combined algorithm directed glucose and insulin infusion with 5 minute blood glucose measurements to direct glucose control; regular insulin and glucose are infused intravenously as adjusted by the algorithm without manual intervention in the group of diabetic individuals under study to adjust the glucose level to a target range of 80-180 mg/dl
glucose control in target range
blood glucose measurements in target range (80-125 mg/dl)
Time frame: data will be evaluated within 6 months after completion of all 40 studies
hypoglycemia
blood glucose \<70 mg/dl
Time frame: data will be evaluated within 6 months after all 40 studies are completed
Plan to share: No — with publication the data will be shared
The record gives a start of Nov 2008, a primary completion of Nov 2029 and a completion of Nov 2029. It does not say whether these dates are actual or estimated.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Nov 2026 → Nov 2029 and completion Nov 2026 → Nov 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.